10.29.12
Del Mar Pharmaceuticals (BC) Ltd. has entered a strategic collaboration with Guangxi Wuzhou Pharmaceutical Co. for the development of VAL-083, (DAG for Injection) in China.
DAG for Injection is approved by the Chinese SFDA as a cancer chemotherapy for the treatment of Chronic Myelogenous Leukemia (CML) and lung cancer. Guangxi is licensed by SFDA to manufacture and sell VAL-083 in China for these indications. DelMar is conducting clinical studies using Guangxi's drug product in the U.S. as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer, and is also researching DAG for Injection in cancers refractory to current therapies.
The companies plan to expand the market in China and to seek regulatory approval for the drug in multiple indications on a global basis. Wuzhou Pharmaceuticals will be the exclusive supplier of DAG for Injection and DelMar will be responsible for development and commercialization.
"This expanded collaboration positions DelMar to unlock the value of our research by benefiting patients in China where our VAL-083 is already approved as a cancer chemotherapy," said Jeffrey Bacha, president and chief executive officer of DelMar.
DAG for Injection is approved by the Chinese SFDA as a cancer chemotherapy for the treatment of Chronic Myelogenous Leukemia (CML) and lung cancer. Guangxi is licensed by SFDA to manufacture and sell VAL-083 in China for these indications. DelMar is conducting clinical studies using Guangxi's drug product in the U.S. as a potential treatment for refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer, and is also researching DAG for Injection in cancers refractory to current therapies.
The companies plan to expand the market in China and to seek regulatory approval for the drug in multiple indications on a global basis. Wuzhou Pharmaceuticals will be the exclusive supplier of DAG for Injection and DelMar will be responsible for development and commercialization.
"This expanded collaboration positions DelMar to unlock the value of our research by benefiting patients in China where our VAL-083 is already approved as a cancer chemotherapy," said Jeffrey Bacha, president and chief executive officer of DelMar.